Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing moderate to severe pain, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, post-operative pain, muscle spasticity, headache, chronic pain, sub-chronic pain and local pain.

Abstract: A system is disclosed for protecting a network against malicious attacks or attempts for unauthorized access. A network is connected to an external network by a number of firewalls. Inspectors detect packets blocked by the firewalls and some or all of the packets are detected to a labyrinth configured to emulated an operational network and response to the packets in order to engage an attacker. Blocked packets may be detected by comparing packets entering and exiting a firewall. Packets for which a corresponding packets are not received within a transit delay may be identified as blocked. Entering and exiting packets may be compared by comparing only header information. A central module may receive information from the inspectors and generate statistical information and generate instructions for the inspectors, such as blacklists of addresses known to be used by attackers.

Abstract: An interconnect architecture device of an aspect includes a processor to generate a transaction that is of a different interconnect protocol than LLI. The interconnect architecture device also includes conversion logic coupled with the processor. The conversion logic is to convert the transaction, which is of the different interconnect protocol than LLI, to an LLI packet. The interconnect architecture device also includes an LLI controller coupled with the conversion logic. The LLI controller is to couple the interconnect architecture device with an LLI link. The LLI controller is to transmit the LLI packet on the LLI link.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g.

Abstract: Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: A structure includes a tetragonal Heusler of the form Mn1+cX, in which X includes an element selected from the group consisting of Ge and Ga, with 0?c?3. The tetragonal Heusler is grown directly on (or more generally, over) a substrate oriented in the direction (001) and of the form YMn1+d, wherein Y includes an element selected from the group consisting of Ir and Pt, with 0?d?4. The tetragonal Heusler and the substrate are in proximity with each other, thereby allowing spin-polarized current to pass from one through the other. This structure may form part of a magnetic tunnel junction magnetoresistive device, and an array of such magnetoresistive devices may together form an MRAM.

Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C24h of at least 0.20 ng/mL.

Abstract: A catheter assembly includes a catheter hub defining an interior cavity and a catheter tube extending distally thereof. A rigid actuator is positioned to extend proximally in the interior cavity and support a seal member positioned thereon in the interior cavity. The seal member includes a central membrane, a distal portion, and a proximal portion. An hourglass shaped actuator cavity is formed in the distal portion and receives a barbed end of the actuator. The outer surface of the seal member is in partial circumferential engagement with the catheter hub to define an air path that allows fluid communication between areas of the interior cavity distal and proximal of the seal member. The seal member may be configured for multi-use and include a biasing member that moves the seal member to force the membrane back over the actuator to close the membrane.

Abstract: A system and method for increasing the vertical situational awareness of a pilot of a host aircraft, comprises rendering symbology on a vertical situation display of the host aircraft, the symbology comprising (1) a traffic scenario including at least the host aircraft and a second aircraft, the second aircraft involved in an ITP transition, and (2) flight level allocation data assigned to the second aircraft by air traffic control.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.

Abstract: Embodiments disclosed obtain a plurality of measurement sets from a plurality of sensors in conjunction with the capture of a sequence of exterior and interior images of a structure while traversing locations in and around the structure. Each measurement set may be associated with at least one image. An external structural envelope of the structure is determined from exterior images of the structure and the corresponding outdoor trajectory of a UE. The position and orientation of the structure and the structural envelope is determined in absolute coordinates. Further, an indoor map of the structure in absolute coordinates may be obtained based on interior images of the structure, a structural envelope in absolute coordinates, and measurements associated with the indoor trajectory of the UE during traversal of the indoor area to capture the interior images.

Abstract: A serial point-to-point link interface to enable communication between a processor and a device, the high speed serial point-to-point link interface including a transmitter to transmit serial data, a receiver to deserialize serial data, and control logic to implement a protocol stack. The protocol stack supports a plurality of power management states, including an active state, a first off state, in which a supply voltage is maintained, and a second off state, in which the supply voltage is not to be provided to the device. The protocol stack provides a default recovery time to allow the device to begin a transition from the first off state to the active state prior to accessing the device. The protocol stack further provides for accessing the device prior to expiration of the default recovery time to complete the transition based on a device-advertised recovery time.

Abstract: A system on a chip (SoC) is provided with a multicore processor, a level-2 (L2) cache controller, an L2 cache, an integrated memory controller, and a serial point-to-point link interface to enable communication between the multicore processor and a device. The interface implements a protocol stack and includes a transmitter to transmit serial data to the device and a receiver to deserialize an incoming serial stream. The protocol stack supports a plurality of power management states, including an active state, a first off state, in which a supply voltage is to be provided to the device, and a second off state, in which the supply voltage is not to be provided to the device. In response to an indication the device is ready to enter the active state, the protocol stack provides for accessing the device prior to expiration of a default recovery time to complete the transition.

Abstract: Embodiments of the present disclosure are directed toward techniques and configurations for an optical coupler. In some embodiments, the device may include an optical waveguide to transmit light input from a light source. The optical waveguide may include a semiconductor layer, having a trench with one facet that comprises an edge formed under an approximately 45 degree angle and another facet formed substantially normal to the semiconductor layer. The edge may interface with another medium to form a mirror to receive inputted light and reflect received light substantially perpendicularly to propagate the received light. Other embodiments may be described and/or claimed.

Abstract: The invention relates to the compounds of formula V or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula V and methods for the treatment of inflammation and pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of pain, oral mucosal inflammatory or oral infectious diseases.

Abstract: An organizational fraud detection (OFD) system and method for flagging one or more transactions as a potential fraudulent activity, in an organization is disclosed. The OFD system comprises: a processor; and a memory communicatively coupled to the processor, wherein the memory stores processor-executable instructions, which, on execution, cause the processor to: receive a suspected transaction for investigation, classify the suspected transaction into one or more groups of fraudulent activity; select, based on the classification, a set of investigation rules for investigating the suspected transaction; determine, based on data selection rules, the data associated with the suspected transaction; ascertain an accuracy score and an impact score associated with the suspected transaction; and classify the suspected transaction as a potential fraudulent activity on at least one of the accuracy score and the impact score exceeding a pre-defined threshold.

Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of asthma and allergy may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of respiratory diseases, respiratory disorders, COPD, bronchitis, brain injury, inflammation, inflammatory skin diseases, asthma, allergic reactions, infections due to acute allergy, bronchospasm, respiratory distress, acute asthma, leukotrienes over activity, 5-LO enzyme activity and cancer.

Abstract: Disclosed are polymerizable mixtures comprising a functionalized ionic gemini surfactant and a thiol-ene crosslinking agent. The polymerizable mixtures that further comprise a polar solvent may be used to form the surfactant into a triply periodic multiply continuous lyotropic phase in the presence of the crosslinking agent. Upon crosslinking, the lyotropic phase morphology is substantially retained.